ArticlePloS one2015
Enrichment of the Cancer Stem Phenotype in Sphere Cultures of Prostate Cancer Cell Lines Occurs through Activation of Developmental Pathways Mediated by the Transcriptional Regulator ΔNp63α.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Identification of placenta-specific protein 1 (PLAC-1) expression on human PC-3 cell line-derived prostate cancer stem cells compared to the tumor parental cells.Discover oncology · 2024Article
- The dual role of p63 in cancer.Frontiers in oncology · 2023Review
- Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Article
- Prostate Cancer Stem Cells: The Role of CD133.Cancers · 2022Review
- Transcriptome profiling reveals that VNPP433-3β, the lead next-generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial-mesenchymal transition and stem cell markers.Molecular carcinogenesis · 2022Article
- EWI2 prevents EGFR from clustering and endocytosis to reduce tumor cell movement and proliferation.Cellular and molecular life sciences : CMLS · 2022Article
- Stem cells from a malignant rat prostate cell line generate prostate cancersAmerican journal of clinical and experimental urology · 2022Article
- BAZ2A-mediated repression via H3K14ac-marked enhancers promotes prostate cancer stem cells.EMBO reports · 2021Article
- TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis.Virchows Archiv : an international journal of pathology · 2021Article
- Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment.Oncotarget · 2021Article
- Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.Journal of experimental & clinical cancer research : CR · 2020Article
- NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis.Journal of experimental & clinical cancer research : CR · 2019Article
- The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors.Materials (Basel, Switzerland) · 2019Review
- Histone Modification Marks Strongly Regulate CDH1 Promoter in Prostospheres as A Model of Prostate Cancer Stem Like Cells.Cell journal · 2019Article
- Interleukin 6 signaling maintains the stem-like properties of bladder cancer stem cells.Translational cancer research · 2019Article
- Sphere‑forming assay vs. organoid culture: Determining long‑term stemness and the chemoresistant capacity of primary colorectal cancer cells.International journal of oncology · 2019Article
- Single-cell RNA-Seq analysis identifies a putative epithelial stem cell population in human primary prostate cells in monolayer and organoid culture conditions.American journal of clinical and experimental urology · 2019Article
- Article
- DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.Oncogene · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer stem cells (CSC) drive prostate cancer tumor survival and metastasis. Nevertheless, the development of specific therapies against CSCs is hindered by the scarcity of these cells in prostate tissues. Suspension culture systems have been reported to enrich CSCs in primary cultures and cell lines. However, the molecular mechanisms underlying this phenomenon have not been fully explored. METHODOLOGY/PRINCIPAL
findingsWe describe a prostasphere assay for the enrichment of CD133+ CSCs in four commercial PCa cell lines: 22Rv1, DU145, LNCaP, and PC3. Overexpression of CD133, as determined by flow cytometric analysis, correlated with an increased clonogenic, chemoresistant, and invasive potential in vitro. This phenotype is concordant to that of CSCs in vivo. Gene expression profiling was then carried out using the Cancer Reference panel and the nCounter system from NanoString Technologies. This analysis revealed several upregulated transcripts that can be further explored as potential diagnostic markers or therapeutic targets. Furthermore, functional annotation analysis suggests that ΔNp63α modulates the activation of developmental pathways responsible for the increased stem identity of cells growing in suspension cultures. CONCLUSIONS/SIGNIFICANCE: We conclude that profiling the genetic mechanisms involved in CSC enrichment will help us to better understand the molecular pathways that underlie CSC pathophysiology. This platform can be readily adapted to enrich and assay actual patient samples, in order to design patient-specific therapies that are aimed particularly against CSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.